The Effect of a Probiotic Administration as an add-on Treatment in Multiple Sclerosis

Summary

It is a randomized, double-blind, placebo-controlled clinical trial whose general objective of this study is to determine the effects of probiotic administration in multiple sclerosis patients. 80 patients with relapsing-remitting multiple sclerosis will be enrolled in the study. Patients will be randomly assigned to receive either a probiotic (n=40) or a placebo (n=40) stratified by type of medication, gender and use of hormonal contraceptive treatment. They will receive a probiotic (Lactibane Iki) or placebo sachet twice a day for six months.

Eligibility

Inclusion Criteria:

* Patients aged 18-55 years, inclusive
* Diagnosis of RRMS (McDonald Criteria 2017 and Lublin phenotype classification 2014)
* Expanded disability status scale (EDSS) score less than or equal to 5.5
* Patients receiving a first line treatment with teriflunomide or dimethyl fumarate at a stable dose, for at least 24 weeks, or patients who are not receiving treatment because they do not want to receive a DMT after the investigator has informed them of their possible respective benefits and possible adverse events
* At enrollment, the patient is not expected to require a change in DMT
* Patients showing a maximum of two new lesions on MRI prior to inclusion
* Females of childbearing potential must have a negative urine pregnancy test result prior to initiation of study product
* For females of childbearing potential: agreement to use adequate contraceptive methods during the treatment period
* Ability to comply with the study protocol
* Patients must sign and date a written informed consent prior to entering the study

Exclusion Criteria:

* Relapse the month before enrollment
* Presence of a new lesion, indicative of radiological activity, on the MRI performed before starting the study
* Use of corticosteroids the month before enrollment
* Use of antibiotics three months before enrollment
* Taking other forms of symbiotic, probiotic, prebiotic and postbiotic supplements three months before enrollment
* Patients suffering from any type of bowel disease
* Pregnant or breastfeeding or intending to become pregnant during the study.
* Be menopausal
* Be a smoker

Conditions1

Browse More Trials